FOXM1 and small cell lung carcinoma: Therefore, to understand the involvement of FOXM1 in CR, we generated cisplatin resistant (CisR) cells for RPM mouse model as well as human SCLC cell lines (Fig. 3B, C) that were validated using cell viability assays that revealed a 10–15-fold boost in the IC50 values for cisplatin in CisR cells compared to their respective naïve counterparts (Fig. 3D–E)).